Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

The glucagon-like peptides (GLP-1 and GLP-2) are processed from the proglucagon polypeptide and secreted in equimolar amounts but have opposite effects on chylomicron (CM) production, with GLP-1 ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

Drucker and three co-winners made discoveries about glucagon-like peptide-1 in their labs. The other recipient of the award, Lotte Bjerre Knudsen, who works for Novo Nordisk, led the way in ...

and promoting glucagon-like peptide-1 (GLP-1) release. This approach holds potential for MASH treatment while maintaining a good safety profile. In this study, the authors first used an ...

In people with type 2 diabetes, both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) were statistically significantly associated with ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet ...